These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 11120938

  • 21. Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model.
    Kidd JM, Abdelraouf K, Asempa TE, Humphries RM, Nicolau DP.
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012755
    [Abstract] [Full Text] [Related]

  • 22. In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial.
    Jones RN, Hare RS, Sabatelli FJ, Ziracin Susceptibility Testing Group.
    J Antimicrob Chemother; 2001 Jan; 47(1):15-25. PubMed ID: 11152427
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
    Hoover J, Lewandowski T, Straub RJ, Novick SJ, DeMarsh P, Aubart K, Rittenhouse S, Zalacain M.
    Antimicrob Agents Chemother; 2016 Jan; 60(1):180-9. PubMed ID: 26482300
    [Abstract] [Full Text] [Related]

  • 24. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.
    Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):845-51. PubMed ID: 11181370
    [Abstract] [Full Text] [Related]

  • 25. Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches.
    Lepak AJ, Trang M, Hammel JP, Sader HS, Bhavnani SM, VanScoy BD, Pogue JM, Ambrose PG, Andes DR, United States Committee on Antimicrobial Susceptibility Testing.
    Antimicrob Agents Chemother; 2023 Apr 18; 67(4):e0145222. PubMed ID: 36946729
    [Abstract] [Full Text] [Related]

  • 26. Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.
    Lepak AJ, Zhao M, Andes DR.
    Antimicrob Agents Chemother; 2017 Jul 18; 61(7):. PubMed ID: 28416551
    [Abstract] [Full Text] [Related]

  • 27. How can we predict bacterial eradication?
    Jacobs MR.
    Int J Infect Dis; 2003 Mar 18; 7 Suppl 1():S13-20. PubMed ID: 12839703
    [Abstract] [Full Text] [Related]

  • 28. Investigation on rifampicin administration from the standpoint of pharmacokinetics/pharmacodynamics in a neutropenic murine thigh infection model.
    Hirai J, Hagihara M, Kato H, Sakanashi D, Nishiyama N, Koizumi Y, Yamagishi Y, Suematsu H, Hanaki H, Mikamo H.
    J Infect Chemother; 2016 Jun 18; 22(6):387-94. PubMed ID: 27029221
    [Abstract] [Full Text] [Related]

  • 29. In vivo pharmacodynamics of new lipopeptide MX-2401.
    Craig WA, Andes DR, Stamstad T.
    Antimicrob Agents Chemother; 2010 Dec 18; 54(12):5092-8. PubMed ID: 20855736
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
    Bhavnani SM, Zhang L, Hammel JP, Rubino CM, Bader JC, Sader HS, Gelone SP, Wicha WW, Ambrose PG.
    J Antimicrob Chemother; 2019 Apr 01; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.
    Van Wart SA, Ambrose PG, Rubino CM, Khariton T, Riccobene TA, Friedland HD, Critchley IA, Bhavnani SM.
    Antimicrob Agents Chemother; 2014 Apr 01; 58(2):885-91. PubMed ID: 24277021
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation.
    Wei XC, Zhao MF, Li X, Xiao X.
    J Clin Pharmacol; 2020 Jun 01; 60(6):768-774. PubMed ID: 32080861
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
    Dowell JA, Goldstein BP, Buckwalter M, Stogniew M, Damle B.
    J Clin Pharmacol; 2008 Sep 01; 48(9):1063-8. PubMed ID: 18633123
    [Abstract] [Full Text] [Related]

  • 34. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M, Browne FA, Jacobs MR, Appelbaum PC.
    Clin Ther; 2003 Jan 01; 25(1):169-77. PubMed ID: 12637118
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.
    Lodise TP, Bosso J, Kelly C, Williams PJ, Lane JR, Huang DB.
    Antimicrob Agents Chemother; 2018 Feb 01; 62(2):. PubMed ID: 29133566
    [Abstract] [Full Text] [Related]

  • 36. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H, Xie J, Chen L, Wang T, Sun J, Zhao Y, Dong Y.
    Int J Infect Dis; 2014 May 01; 22():35-40. PubMed ID: 24603161
    [Abstract] [Full Text] [Related]

  • 37. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection.
    Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Moller N.
    Antimicrob Agents Chemother; 2000 May 01; 44(5):1247-54. PubMed ID: 10770759
    [Abstract] [Full Text] [Related]

  • 38. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.
    Vostrov SN, Kononenko OV, Lubenko IY, Zinner SH, Firsov AA.
    Antimicrob Agents Chemother; 2000 Apr 01; 44(4):879-84. PubMed ID: 10722485
    [Abstract] [Full Text] [Related]

  • 39. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR.
    J Antimicrob Chemother; 2009 Dec 01; 64(6):1226-9. PubMed ID: 19833635
    [Abstract] [Full Text] [Related]

  • 40. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.
    Bland CM, Pai MP, Lodise TP.
    Pharmacotherapy; 2018 Dec 01; 38(12):1229-1238. PubMed ID: 30403305
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.